Author details

Full Name

BjÃ¶rn Nilsson

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36993312	Genetic regulation of fetal hemoglobin across global populations.	medRxiv	2023
37600847	AliGater: a framework for the development of bioinformatic pipelines for large-scale, high-dimensional cytometry data.		2023
37400429	Publisher Correction: Deficit of homozygosity among 1.52 million individuals and genetic causes of recessive lethality.	Nat Commun	2023
37323567	Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens.		2023
37301908	Deficit of homozygosity among 1.52 million individuals and genetic causes of recessive lethality.	Nat Commun	2023
35013207	Functional dissection of inherited non-coding variation influencing multiple myeloma risk.	Nat Commun	2022
36513657	Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.	Nat Commun	2022
34782614	Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk.	Blood Cancer J	2021
33583942	Characterization of rare germline variants in familial multiple myeloma.	Blood Cancer J	2021
33627649	Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing.	Nature Communications	2021
33875642	Germline variants at SOHLH2 influence multiple myeloma risk.	Blood Cancer J	2021
34568833	<i>ZBTB33</i> is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing.	Blood Cancer Discov	2021
32555370	S100A6 is a critical regulator of hematopoietic stem cells.	Leukemia	2020
32433745	Search for multiple myeloma risk factors using Mendelian randomization.	Blood advances	2020
31913320	Genetic predisposition for multiple myeloma.	Leukemia	2020
32460032	CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.	Cell Rep	2020
32665696	Correction: S100A6 is a critical regulator of hematopoietic stem cells.	Leukemia	2020
31341961	Essential genes shape cancer genomes through linear limitation of homozygous deletions.	Communications Biology	2019
30967618	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.	Leukemia	2019
31429796	Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.	Hum Genomics	2019
31363079	Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden.	Blood Cancer Journal	2019
31359027	MPRAscore: robust and non-parametric analysis of massively parallel reporter assays.		2019
29695719	The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.	Nature Communications	2018
30602759	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.	Blood Cancer J	2018
30213928	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.	Nat Commun	2018
27889611	Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms' tumor gene 1 (WT1) protein in leukemic cells.	Biochemical and Biophysical Research Communications	2017
28628107	Identification of sequence variants influencing immunoglobulin levels.	Nat Genet	2017
28622301	Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.	Blood Cancer J	2017
29263835	Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations.	NPJ Genom Med	2017
29296704	Direct evidence for a polygenic etiology in familial multiple myeloma.	Blood Adv	2017
29152069	The transcriptional coregulator <i>NAB2</i> is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells.	Oncotarget	2017
28084402	SMIM1 variants rs1175550 and rs143702418 independently modulate Vel blood group antigen expression.	Sci Rep	2017
27612989	Distinct global binding patterns of the Wilms tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells.	Haematologica	2017
28264936	Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with <i>TP53</i> mutations.	EMBO Mol Med	2017
27070706	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.	Cancer Cell	2016
27197230	Hematopoietic Age at Onset of Triple-Negative Breast Cancer Dictates Disease Aggressiveness and Progression.	Cancer Research	2016
26832662	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.	Cancer Cell	2016
26997282	Genome-wide RNAi Screen Identifies Cohesin Genes as Modifiers of Renewal and Differentiation in Human HSCs.	Cell Reports	2016
27363682	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.	Nat Commun	2016
27122612	IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections.	Science Translational Medicine	2016
26007630	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.	Nat Commun	2015
25873171	Antagonistic human FcÎ³RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.	Cancer Cell	2015
25216995	The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.	Mol Cancer	2014
24385542	Robust isolation of malignant plasma cells in multiple myeloma.	Blood	2014
23267175	Ultranet: efficient solver for the sparse inverse covariance selection problem in gene network modeling.		2013
23871158	Leukemia associated mutant Wilms' tumor gene 1 protein promotes expansion of human hematopoietic progenitor cells.	Leuk Res	2013
23689072	Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors.	Cancer Discov	2013
23563606	Homozygosity for a null allele of SMIM1 defines the Vel-negative blood group phenotype.	Nature Genetics	2013
22222600	Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.	Leukemia	2012
23133590	A framework for regularized non-negative matrix factorization, with application to the analysis of gene expression data.	PLoS ONE	2012